Inify Laboratories: Key information regarding Repair Issue

Inify Laboratories said it will carry out a fully guaranteed repair issue of new shares following a private placement, targeting gross proceeds of approximately NOK 8 million via a maximum of 2,304,563 new shares at a subscription price of NOK 3.50 per share; the terms were announced 17 December 2025, the last trading day including rights was 16 December (ex-date 17 December) and the record date is 18 December 2025, with expected approval on or around 27 January 2026. The repair issue will be directed pro rata to existing shareholders (excluding those eligible for the private placement); VPS-registered holders will receive non-tradable subscription rights while Euroclear-registered holders receive an application form. The financing represents a dilutive equity raise to shore up capital after the private placement, is fully guaranteed which reduces execution risk, and will affect the share count of the Stockholm-headquartered, Euronext Growth Oslo‑listed diagnostics group that operates AI-assisted histopathology labs in Sweden and the UK.

Analysis

Inify Laboratories has announced a fully guaranteed repair issue to raise gross proceeds of approximately NOK 8 million through up to 2,304,563 new shares at a subscription price of NOK 3.50 per share; terms were published 17 December 2025, with last trade including rights 16 December, ex-date 17 December, record date 18 December and expected approval on or around 27 January 2026. The repair issue is directed pro rata to existing shareholders who were not eligible for the private placement, which materially differentiates treatment between VPS-registered holders (who receive non-tradable subscription rights) and Euroclear-registered holders (who receive an application form but no tradable rights).

The fully guaranteed nature reduces execution risk and ensures the intended capital is raised, but the issuance at NOK 3.50 is dilutive to current holders and likely to exert near-term downward pressure on the share count and per-share metrics. Market signals show a mildly negative sentiment score of -0.25 and a modest positive market_impact_score of 0.25, indicating cautious investor reaction despite reduced execution risk.

Operationally, Inify's business—AI-assisted histopathology diagnostics with scalable labs in Sweden and the UK and a proprietary AI aiding pathologists—remains the strategic rationale for investor interest, but the equity raise signals immediate cash needs following the private placement. Investors should weigh the near-term capital-structure dilution and subscription mechanics against the company’s long-term growth case and await clarity on the use of proceeds and approval documentation expected late January.

Key Decisions for Investors

• Calculate pro-forma share count and dilution impact at NOK 3.50 and, if you are VPS-registered and wish to avoid dilution, consider participating pro rata in the Repair Issue
• If you are Euroclear-registered or ineligible for subscription rights, consider hedging or reducing exposure before the record date to avoid asymmetric dilution and administrative complexity
• Monitor the approval on or around 27 January 2026 and demand disclosure on use of proceeds; defer adding material new exposure until deployment and operational milestones are clearer
• Treat the financing as a near-term liquidity/capital-structure risk but retain a constructive view on the company’s scalable AI-assisted diagnostics franchise for long-term holders; size positions accordingly
• For significant holders, contact management (CEO Fredrik Palm) to clarify allocation mechanics, the guarantee structure and any follow-up financing plans